Peripheral t cell lymphoma in 2013
This presentation is the property of its rightful owner.
Sponsored Links
1 / 51

Peripheral T-Cell Lymphoma in 2013 PowerPoint PPT Presentation

  • Uploaded on
  • Presentation posted in: General

Peripheral T-Cell Lymphoma in 2013. Program Goal. WHO 2008 Classification of Mature T/NK-Cell Neoplasms. Use of the Term PTCL. PTCL, PTCL Mature (Post-Thymic) T-Cell Lymphomas. International PTCL Study: Major NHL Types by Region.

Download Presentation

Peripheral T-Cell Lymphoma in 2013

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript

Peripheral t cell lymphoma in 2013

Peripheral T-Cell Lymphoma in 2013

Program goal

Program Goal

Who 2008 classification of mature t nk cell neoplasms

WHO 2008 Classification of Mature T/NK-Cell Neoplasms

Use of the term ptcl

Use of the Term PTCL

Ptcl ptcl mature post thymic t cell lymphomas

PTCL, PTCL Mature (Post-Thymic) T-Cell Lymphomas

International ptcl study major nhl types by region

International PTCL Study: Major NHL Types by Region

Key points in the pathology characteristics of the most common subtypes of ptcl

Key Points in the Pathology Characteristics of the Most Common Subtypes of PTCL

Alk and alcl


Outcomes by ptcl subtypes

Outcomes by PTCL Subtypes

Prognostic indices for ptcl

Prognostic Indices for PTCL

Peripheral t cell lymphoma in 2013

Autologous Stem Cell Transplantation as First-line Therapy in PTCL: Results of a Prospective Multicenter Study

Chop first line treatment of ptcl

CHOP: First-line Treatment of PTCL

Alemtuzumab a chemotherapy first line treatment of ptcl

Alemtuzumab (A) + ChemotherapyFirst-line treatment of PTCL

Chop and non chop first line treatment of ptcl

CHOP+ and Non-CHOP: First-line Treatment of PTCL

Peripheral t cell lymphoma in 2013

Treatment and Prognosis of Mature T-Cell and NK-Cell Lymphoma: Event-Free Survival of Younger Patients

Peripheral t cell lymphoma in 2013

Treatment and Prognosis of Mature T-Cell and NK-Cell Lymphoma: Event-free Survival of Younger Patients (cont)

Autologous stem cell transplantation as first line therapy in ptcl survival

Autologous Stem Cell Transplantation as First-line Therapy in PTCL: Survival

Prognostic factors in trials of asct in first remission

Prognostic Factors in Trials of ASCT in First Remission

Ice and planned asct for relapsed refractory t cell lymphoma pfs from ice

ICE and Planned ASCT for Relapsed/Refractory T-Cell Lymphoma: PFS From ICE

Cibmtr auto and allo for ptcl outcomes excluding patients in cr1

CIBMTR Auto and Allo for PTCL: Outcomes Excluding Patients in CR1

Retrospective analyses of allogeneic stem cell transplantation for ptcl

Retrospective Analyses of Allogeneic Stem-Cell Transplantation for PTCL

Approved agents in relapsed refractory ptcl

Approved Agents in Relapsed/Refractory PTCL

Propel adverse events gr 3 occurring in 3 of patients n 111

PROPEL: Adverse Events ≥ Gr 3 Occurring in ≥ 3% of Patients (n = 111)

Treatment related adverse events with romidepsin in 20 of patients n 131

Treatment-related Adverse Events With Romidepsin in ≥ 20% of Patients (N = 131)

Brentuximab vedotin phase 2 study in relapsed refractory systemic alcl

Brentuximab Vedotin: Phase 2 Study in Relapsed/Refractory Systemic ALCL

Brentuximab vedotin in relapsed alcl toxicities

Brentuximab Vedotin in Relapsed ALCL: Toxicities

Brentuximab best clinical response by disease diagnosis

Brentuximab: Best Clinical Response by Disease Diagnosis

Brentuximab maximum tumor volume reduction by frequency of cd30 cells

Brentuximab: Maximum Tumor Volume Reduction by Frequency of CD30+ Cells

Front line therapy study design combination therapy arms

Front-line Therapy: Study Design (Combination Therapy Arms)

Front line therapy best response by disease diagnosis

Front-line Therapy: Best Response by Disease Diagnosis

Bendamustine in t cell lymphoma bently trial

Bendamustine in T-Cell Lymphoma (BENTLY Trial)

Lenalidomide in relapsed refractory tcl phase 2 trial

Lenalidomide in Relapsed/Refractory TCL: Phase 2 Trial

Belinostat ptcl response assessed by central review

Belinostat: PTCL Response Assessed by Central Review

Belinostat response rate by cprg lymphoma diagnosis

Belinostat: Response Rate by CPRG Lymphoma Diagnosis

Belinostat grade 3 nonhematologic aes in patients with r r ptcl n 120

Belinostat: Grade ≥3 Nonhematologic AEs in Patients With R/R PTCL (N=120)

Mln8237 response pr cr by histology

MLN8237: Response (PR + CR) by Histology

Ipi 145 a pi3k inhibitor

IPI-145: A PI3K-δ,γ Inhibitor

Early signs of clinical activity of ipi 145 in t cell lymphoma

Early Signs of Clinical Activity of IPI-145 in T-Cell Lymphoma

Mogamulizumab kw 0761 anti ccr4 monoclonal antibody

Mogamulizumab (KW-0761)Anti-CCR4 Monoclonal Antibody

Recommended approach to patients with relapsed ptcl nos aitl alcl

Recommended Approach to Patients With Relapsed PTCL (NOS, AITL, ALCL)



Abbreviations cont

Abbreviations (cont)

Abbreviations cont1

Abbreviations (cont)

Abbreviations cont2

Abbreviations (cont)



References cont

References (cont)

References cont1

References (cont)

References cont2

References (cont)

References cont3

References (cont)

References cont4

References (cont)

References cont5

References (cont)

  • Login